For years, U.S. vaccine experts have issued a universal recommendation for Covid vaccines. That could change soon.

Researchers aim to develop a universal vaccine platform that could protect against both COVID-19 and influenza without annual ...

The plans amount to an extraordinary flex of Robert F. Kennedy Jr.’s power as health secretary to make decisions ordinarily ...

A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.

The Food and Drug Administration announced Tuesday it has picked a new head of its center charged with vaccine approvals ... speed up the development of vaccines during the COVID-19 pandemic.

and comprehensive preparedness," by focusing on "in-house development" of vaccines instead of projects from outside researchers. It is also planning to develop other vaccines for COVID-19 using ...

Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, ...

R&D expenses were $89 million, compared to $93 million a year ago, primarily due to reductions in overall expenditures related to COVID-19 vaccine development. SG&A expenses reached $48 million ...

Rudman Spergel, MD, director of clinical development at Moderna ... the technology to create one of the world’s first COVID-19 vaccines. In 2023, the company announced results from a phase ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced its business update and financial results for the first quarter of ...